Timing of headache after COVID-19 vaccines and its association with cerebrovascular events: An analysis of 41,700 VAERS reports

Article Rheumatology

COVID-19 vaccine safety and nocebo-prone associated hesitancy in patients with systemic rheumatic diseases: a cross-sectional study

George E. Fragoulis et al.

Summary: The study found no new safety signals for COVID-19 vaccination. The vaccination campaign should target SRD patients with a tendency towards nocebo-prone and negative influenza vaccination behavior.

RHEUMATOLOGY INTERNATIONAL (2022)

Add to Collection

Article Clinical Neurology

Neurological Events Reported after COVID-19 Vaccines: An Analysis of Vaccine Adverse Event Reporting System

Jennifer A. Frontera et al.

Summary: This study analyzed data collected from the US Vaccine Adverse Event Reporting System from January 1, 2021 to June 14, 2021. The study found that the rates of neurological events following COVID vaccination were rare, while the rates of neurological complications following acute COVID infection were significantly higher.

ANNALS OF NEUROLOGY (2022)

Add to Collection

Review Emergency Medicine

Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines

Brit Long et al.

Summary: This review summarized the background, evaluation, and management of vaccine-induced immune thrombotic thrombocytopenia (TTS). TTS is mainly associated with the Oxford-AstraZeneca and Johnson & Johnson vaccines, characterized by thrombosis and thrombocytopenia, with a low overall incidence.

AMERICAN JOURNAL OF EMERGENCY MEDICINE (2021)

Add to Collection

Article Public, Environmental & Occupational Health

COVID-19 vaccine hesitancy among medical students

Victoria C. Lucia et al.

Summary: Medical students generally have positive attitudes towards COVID-19 vaccines, but some are hesitant to participate in vaccine trials or get vaccinated immediately. Students willing to get vaccinated right away are more likely to trust public health experts and have fewer concerns about side effects, while concerns about serious side effects are associated with lower intent to participate in vaccine trials.

JOURNAL OF PUBLIC HEALTH (2021)

Add to Collection

Article Clinical Neurology

Characteristics and Outcomes of Patients With Cerebral Venous Sinus Thrombosis in SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia

Mayte Sanchez van Kammen et al.

Summary: This study found that patients with cerebral venous sinus thrombosis after COVID-19 vaccination who met the criteria for TTS had distinct clinical characteristics, high prevalence, and high mortality rates.

JAMA NEUROLOGY (2021)

Add to Collection

Review Clinical Neurology

Headache secondary to cerebrovascular disease

John F. Rothrock et al.

Summary: Headache is a prominent symptom in various cerebrovascular diseases. The presence of headache with focal neurological deficits warrants immediate diagnosis and treatment. Migraine is also linked to an increased risk of stroke.

CEPHALALGIA (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Geographical distribution of TTS cases following AZD1222 (ChAdOx1 nCoV-19) vaccination

Karina Soboleva et al.

Lancet Global Health (2021)

Add to Collection

Article Medicine, General & Internal

US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021

Isaac See et al.

Summary: Cases of CVST with thrombocytopenia following Ad26.COV2.S vaccination have been reported in the US, leading to serious outcomes. This case series may provide guidance for clinical management and further investigation into the potential relationship between Ad26.COV2.S vaccine and CVST with thrombocytopenia.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Review Public, Environmental & Occupational Health

COVID-19 Vaccine Hesitancy in the United States: A Systematic Review

Farah Yasmin et al.

Summary: A systematic review on COVID-19 vaccine uptake in the US revealed varying acceptance rates, with hesitancy particularly high among Black/African Americans and pregnant/breastfeeding women, while lower among males. Efforts need to be made to address these disparities and revise vaccination plans accordingly.

FRONTIERS IN PUBLIC HEALTH (2021)

Add to Collection

Article Medicine, General & Internal

Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination

Marie Scully et al.

Summary: 23 cases of thrombotic thrombocytopenia were reported after receiving the AstraZeneca vaccine, incited by antibodies to platelet factor 4 and unrelated to heparin therapy. Avoidance of platelet transfusion and consideration of nonheparin anticoagulant and intravenous immune globulin are recommended for treatment.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study

Anton Pottegard et al.

Summary: This study assessed rates of cardiovascular and haemostatic events in Denmark and Norway after vaccination with the Oxford-AstraZeneca vaccine ChAdOx1-S, finding increased rates of venous thromboembolic events among recipients. Despite slightly higher rates of thrombocytopenia/coagulation disorders and bleeding, the overall safety outcomes were largely reassuring.

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Clinical Neurology

COVID-19 Vaccine-Associated Cerebral Venous Thrombosis in Germany

Joerg B. Schulz et al.

Summary: The study found a higher incidence of cerebral sinus and venous thrombosis (CVT) after ChAdOx1 vaccination in Germany, especially among females. Among the 45 CVT patients, 26 were highly probable cases of vaccine-induced immune thrombotic thrombocytopenia (VITT).

ANNALS OF NEUROLOGY (2021)

Add to Collection

Article Immunology

Blood clots and bleeding events following BNT162b2 and ChAdOx1 nCoV-19 vaccine: An analysis of European data

Luigi Cari et al.

Summary: The study compared the frequency of severe adverse events (SAEs) between ChAdOx1 nCoV-19 Covid-19 and BNT162b2 Covid-19 vaccines in Europe, showing that recipients of ChA vaccine have higher risks in bleeding, thrombocytopenia, and blood clots. Young people and women of reproductive age may be at higher risk following ChA vaccination.

JOURNAL OF AUTOIMMUNITY (2021)

Add to Collection

Article Clinical Neurology

Delayed headache after COVID-19 vaccination: a red flag for vaccine induced cerebral venous thrombosis

David Garcia-Azorin et al.

Summary: Cerebral venous thrombosis (CVT) can occur following COVID-19 vaccination, especially in recipients of adenovirus vector-based vaccines. Headache is a common symptom of CVT, associated with intracranial hemorrhage but not directly linked to death.

JOURNAL OF HEADACHE AND PAIN (2021)

Add to Collection

Article Hematology

Comparison of adverse drug reactions among four COVID-19 vaccines in Europe using the EudraVigilance database: Thrombosis at unusual sites

Maria Abbattista et al.

Summary: This study assessed the reporting rate of cerebral vein thrombosis (CVT) as an adverse drug reaction for four COVID-19 vaccines authorized in Europe. The results showed that all four vaccines were associated with CVT and thrombocytopenia.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2021)

Add to Collection

Article Medicine, General & Internal

Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study

Richard J. Perry et al.

Summary: The study documented cases of cerebral venous thrombosis after COVID-19 vaccination, finding that patients with VITT were younger, had more intracranial and extracranial thrombosis, and experienced worse outcomes compared to non-VITT patients. Treatments with non-heparin anticoagulants and intravenous immunoglobulin may improve outcomes in VITT-associated cerebral venous thrombosis.

LANCET (2021)

Add to Collection

Article Biotechnology & Applied Microbiology

A comprehensive analysis of the efficacy and safety of COVID-19 vaccines

Changjing Cai et al.

Summary: The numbers of COVID-19 cases and deaths are increasing, with vaccine efficacy exceeding 70% and RNA-based vaccines being the most effective at 94.29%. The most common vaccine-related adverse reactions are pain, fatigue, and headache, with most reactions being mild, although severe reactions such as thromboembolic events have been identified.

MOLECULAR THERAPY (2021)

Add to Collection

Article Medicine, General & Internal

Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis

Sue Pavord et al.

Summary: Phenotypes of VITT were defined in 220 patients in the United Kingdom who presented a median of 14 days after the first ChAdOx1 nCoV-19 vaccination. Half had cerebral venous sinus thrombosis, a third of whom also had intracranial hemorrhage. Mortality was 22%. Intravenous immune globulin may reverse VITT.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study

Julia Hippisley-Cox et al.

Summary: The study found increased risks of haematological and vascular events leading to hospital admission or death within short time intervals after first doses of the ChAdOx1 nCoV-19 and BNT162b2 mRNA vaccines. The risks of these events were higher and more prolonged after SARS-CoV-2 infection compared to vaccination in the same population.

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Clinical Neurology

Clinical characteristics of headache after vaccination against COVID-19 (coronavirus SARS-CoV-2) with the BNT162b2 mRNA vaccine: a multicentre observational cohort study

Carl H. Goebel et al.

Summary: The study aims to examine in detail the clinical characteristics of headaches occurring after vaccination against COVID-19 with the BNT162b2 mRNA vaccine. Results show that headaches typically occur around 18 hours after vaccination and last about 14 hours, with most being bilateral and located in the forehead and temples. The pain is usually pressing in nature, and common accompanying symptoms include fatigue, exhaustion, and muscle pain.

BRAIN COMMUNICATIONS (2021)

Add to Collection

Review Clinical Neurology